NMTR 9 Meters Biopharma, Inc. Stock Quote

NMTR [NASD]

Index	-	P/E	-	EPS (ttm)	-0.17	Insider Own	1.00%	Shs Outstand	258.24M	Perf Week	16.69%
Market Cap	113.37M	Forward P/E	-	EPS next Y	-0.18	Insider Trans	19.87%	Shs Float	248.20M	Perf Month	5.38%
Income	-42.70M	PEG	-	EPS next Q	-0.04	Inst Own	29.50%	Short Float	5.58%	Perf Quarter	-23.02%
Sales	-	P/S	-	EPS this Y	74.00%	Inst Trans	-4.67%	Short Ratio	10.28	Perf Half Y	-54.01%
Book/sh	0.12	P/B	3.99	EPS next Y	-6.30%	ROA	-80.50%	Target Price	4.60	Perf Year	-59.81%
Cash/sh	0.16	P/C	3.05	EPS next 5Y	-	ROE	-94.40%	52W Range	0.35 - 1.55	Perf YTD	-51.13%
Dividend	-	P/FCF	-	EPS past 5Y	57.80%	ROI	-	52W High	-69.14%	Beta	-2.58
Dividend %	-	Quick Ratio	4.80	Sales past 5Y	-	Gross Margin	-	52W Low	36.62%	ATR	0.05
Employees	21	Current Ratio	4.80	Sales Q/Q	-	Oper. Margin	-	RSI (14)	54.15	Volatility	10.63% 11.33%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-71.00%	Profit Margin	-	Rel Volume	0.66	Prev Close	0.47
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	1.35M	Price	0.48
Recom	1.70	SMA20	12.05%	SMA50	-4.80%	SMA200	-46.30%	Volume	924,165	Change	1.77%

Jul-08-21

Initiated

BMO Capital Markets

Outperform

Jun-04-21

Initiated

Citigroup

Buy

May-19-22 08:00AM	9 Meters Biopharma to Exhibit at Digestive Disease Week 2022 ACCESSWIRE
May-18-22 08:00AM	9 Meters Biopharma Presents Preclinical Data at the 2022 American Thoracic Society International Conference on the Use of Larazotide in Idiopathic Pulmonary Fibrosis ACCESSWIRE -5.15%
May-16-22 07:00AM	9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2022 ACCESSWIRE +8.87%
May-05-22 08:00AM	9 Meters Biopharma to Present at the H.C. Wainwright Global Investment Conference and the LifeSci Partners Immunology & Inflammation Symposium ACCESSWIRE -7.89%
Apr-20-22 09:00AM	9 Meters Biopharma and Celiac.com Announce Collaboration to Support Clinical Trial Enrollment in 9 Meter's Phase 3 Study for Celiac Disease ACCESSWIRE
Apr-13-22 07:00AM	9 Meters Biopharma Announces Allowance of Patent for Anti-GIP Monoclonal Antibody NM-136 for the Treatment of Serious Metabolic Conditions ACCESSWIRE +5.93%
Mar-23-22 07:00AM	9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 2021 ACCESSWIRE -5.19%
Mar-21-22 08:00AM	9 Meters Biopharma to Present at the Maxim Group 2022 Virtual Growth Conference ACCESSWIRE
Mar-09-22 08:00AM	9 Meters Biopharma to Present at the Oppenheimer 32nd Annual Healthcare Conference ACCESSWIRE +11.62%
Mar-02-22 08:00AM	9 Meters Biopharma Announces a Collaboration with NYU Langone Health Investigating NM-102 as a Potential Treatment for an Autoimmune Disorder ACCESSWIRE
Feb-28-22 04:15PM	9 Meters Biopharma Provides Clinical Update on Late-Stage Pipeline Products Vurolenatide for Short Bowel Syndrome and Larazotide for Celiac Disease ACCESSWIRE
Feb-25-22 08:00AM	9 Meters Biopharma Announces Publication of Data on Larazotide for the Treatment of Multisystem Inflammatory Syndrome in Children (MIS-C) ACCESSWIRE
Feb-09-22 08:00AM	9 Meters Biopharma to Present at the 2022 BIO CEO & Investor Conference ACCESSWIRE
Feb-08-22 01:38PM	Paradigm, Strategies in Wealth Management, LLC Buys iShares iBonds Dec 2023 Term Corporate ETF, ... GuruFocus.com
Jan-24-22 08:00AM	9 Meters Biopharma Announces Allowance of Patent for NM-102 in Combination with Immune Checkpoint Inhibitors ACCESSWIRE
Jan-21-22 11:40AM	Raleigh public company adds former Biogen exec to C-suite American City Business Journals -5.10%
Jan-18-22 08:00AM	9 Meters Biopharma Appoints Bethany Sensenig as Chief Financial Officer ACCESSWIRE
Jan-04-22 07:30AM	9 Meters Biopharma, Inc. to Participate in the following Virtual January Investor Conferences ACCESSWIRE
Jan-03-22 07:30AM	9 Meters Biopharma Appoints Sarah Liu as Chief Commercial Officer and Al Medwar as Senior Vice President of Investor Relations & Corporate Communications ACCESSWIRE
Dec-16-21 11:17AM	2 Strong Buy Penny Stocks That Can Deliver Over 200% Gains Next Year TipRanks +7.39%
Dec-15-21 07:30AM	9 Meters Biopharma, Inc. Awards Unrestricted Educational Grant Funding to Carol Rees Parrish, M.S., RDN, for Short Bowel Syndrome Education ACCESSWIRE
Nov-18-21 10:00AM	Down 20.5% in 4 Weeks, Here's Why You Should You Buy the Dip in 9 Meters Biopharma, Inc. (NMTR) Zacks
Nov-15-21 07:30AM	9 Meters Biopharma Provides Business Update and Reports Financial Results for the Third Quarter 2021 ACCESSWIRE
Nov-10-21 07:30AM	9 Meters Biopharma, Inc. Announces Immuno-Oncology Collaboration with Gustave Roussy for NM-102, a Gut Microbiome Modulator ACCESSWIRE
Nov-09-21 07:30AM	9 Meters Biopharma, Inc. to Present at the 12th Annual Jefferies London Healthcare Conference ACCESSWIRE
Oct-26-21 07:30AM	9 Meters Biopharma, Inc. Presents Pharmacokinetic Data from Phase 1b/2a Study with Vurolenatide, Currently in Phase 2 for Short Bowel Syndrome, at the American College of Gastroenterology (ACG) 2021 Annual Scientific Meeting ACCESSWIRE
Oct-19-21 07:30AM	9 Meters Biopharma, Inc. to Present Data on Therapeutic Candidate in Short Bowel Syndrome at the American College of Gastroenterology (ACG) 2021 Annual Scientific Meeting ACCESSWIRE
Oct-04-21 07:30AM	9 Meters Biopharma, Inc. Appoints Samantha Ventimiglia to Board of Directors ACCESSWIRE
Sep-27-21 07:30AM	9 Meters Biopharma, Inc. Announces Partnership with Non-Profit Gluten-Free Food Pantry Organization Mend Hunger ACCESSWIRE
Sep-22-21 08:15AM	9 Meters Biopharma, Inc. to Present at the Cantor Virtual Global Healthcare Conference ACCESSWIRE
Sep-15-21 08:15AM	9 Meters Biopharma, Inc. to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit ACCESSWIRE
Sep-08-21 08:15AM	9 Meters Biopharma, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference ACCESSWIRE
Sep-01-21 08:15AM	9 Meters Biopharma, Inc. to Participate in Citi's 16th Annual BioPharma Virtual Conference 2021 ACCESSWIRE
Aug-16-21 08:15AM	9 Meters Biopharma, Inc. Announces Collaboration with EBRIS Foundation for Planned Phase 2 Study of Larazotide for the Treatment of Multisystem Inflammatory Syndrome in Children (MIS-C) Resulting from COVID-19 ACCESSWIRE
Aug-12-21 08:30AM	9 Meters Biopharma Provides Business Update and Reports Financial Results for the Second Quarter 2021 ACCESSWIRE
Aug-05-21 08:30AM	9 Meters Biopharma, Inc. to participate in BMO Capital Markets' "Biopharma Spotlight Series: Innovation in GI" ACCESSWIRE
Jul-19-21 08:30AM	9 Meters Biopharma, Inc. Announces the Acquisition of Humanized Anti-GIP Monoclonal Antibody from Lobesity ACCESSWIRE
Jul-12-21 08:42AM	Implied Volatility Surging for 9 Meters Biopharma (NMTR) Stock Options Zacks
Jul-08-21 07:30AM	9 Meters Biopharma, Inc. To Present at the William Blair Biotech Focus Conference ACCESSWIRE +20.39%
Jun-28-21 07:30AM	9 Meters Added to Russell 2000(R) and 3000(R) Indexes ACCESSWIRE -5.00%
Jun-22-21 10:43AM	Could The 9 Meters Biopharma, Inc. (NASDAQ:NMTR) Ownership Structure Tell Us Something Useful? Simply Wall St.
Jun-14-21 07:30AM	9 Meters Announces Initiation of Phase 2 VIBRANT Study of Vurolenatide for Short Bowel Syndrome ACCESSWIRE
Jun-09-21 07:30AM	9 Meters Biopharma, Inc. to Present at 2021 BIO Digital ACCESSWIRE
Jun-01-21 07:30AM	9 Meters Biopharma, Inc. to Present at the Jefferies Virtual Healthcare Conference ACCESSWIRE
May-26-21 08:30AM	9 Meters Biopharma, Inc. Announces Publication in Journal of Clinical Investigation Describing Successful Use of Larazotide for Treating Multisystem Inflammatory Syndrome in Children (MIS-C) resulting from COVID-19 Infection ACCESSWIRE
May-19-21 10:11AM	Is the Options Market Predicting a Spike in 9 Meters Biopharma (NMTR) Stock? Zacks
May-18-21 10:15AM	CORRECTION 9 Meters Biopharma, Inc. to Present at Oppenheimer's Rare & Orphan Disease Summit ACCESSWIRE
07:30AM	9 Meters Biopharma, Inc. to Present at Oppenheimer's Rare & Orphan Disease Summit ACCESSWIRE
May-17-21 07:30AM	9 Meters Biopharma, Inc. Receives USAN Approval to Use the Designated Nonproprietary Name Vurolenatide for Its Long-Acting GLP-1 Agonist for Short Bowel Syndrome ACCESSWIRE
Apr-21-21 07:30AM	9 Meters Biopharma, Inc. to Participate in the Truist Securities 7th Annual Life Sciences Summit ACCESSWIRE
Apr-19-21 07:30AM	9 Meters Biopharma, Inc. Announces Collaboration with the Duke Clinical Research Institute to Support 9 Meters' Program in Short Bowel Syndrome ACCESSWIRE
Apr-12-21 07:30AM	9 Meters Biopharma, Inc. and Celiac Disease Foundation Announce Collaboration to Support Clinical Trial Enrollment in 9 Meters' Phase 3 CeDLara Study ACCESSWIRE
Apr-05-21 04:15PM	9 Meters Biopharma Announces Closing of Offering of Common Stock ACCESSWIRE
Mar-30-21 10:30PM	9 Meters Biopharma Prices Public Offering of Common Stock ACCESSWIRE
04:14PM	9 Meters Biopharma Announces Proposed Public Offering of Common Stock ACCESSWIRE
Mar-24-21 04:05AM	Did 9 Meters Biopharma, Inc. (NASDAQ:NMTR) Insiders Buy Up More Shares? Simply Wall St. -12.67%
Mar-22-21 04:00PM	9 Meters Biopharma Provides Business Update and Reports Financial Results for the Fourth Quarter and Full Year 2020 ACCESSWIRE
Mar-15-21 07:30AM	9 Meters Biopharma Hosting Key Opinion Leader Webinar on Short Bowel Syndrome and NM-002 Program Update ACCESSWIRE
Mar-10-21 07:30AM	9 Meters Biopharma, Inc. to Participate in the following Virtual March Investor Conferences ACCESSWIRE
Mar-09-21 06:30AM	9 Meters Biopharma, Inc. Announces Chief Medical Officer's Presentation at NIH's Accelerating Progress in Celiac Disease Workshop ACCESSWIRE +12.68%
Mar-01-21 07:30AM	9 Meters Biopharma, Inc. Appoints Michael Rice to Board of Directors ACCESSWIRE
Feb-10-21 07:30AM	9 Meters Biopharma, Inc. to Present at the 23rd Annual BIO CEO & Investor Conference ACCESSWIRE
Feb-04-21 08:12AM	9 Meters Biopharma (NMTR) is Overbought: Is A Drop Coming? Zacks
Feb-03-21 07:30AM	9 Meters Biopharma, Inc. highlighted at upcoming Truist Securities' CEO Strategic Vision Conference Call Series ACCESSWIRE +20.55%
Feb-01-21 07:30AM	9 Meters Biopharma, Inc. Announces Research & Development Day on Short Bowel Syndrome ACCESSWIRE +7.91%
Jan-05-21 12:41PM	2 Strong Buy Penny Stocks That Could Deliver Massive Returns TipRanks +27.53%
Dec-21-20 07:30AM	9 Meters Biopharma Announces Agreement with the European Biomedical Research Institute of Salerno (EBRIS) to Continue Evaluation of Larazotide for COVID-19 Respiratory Complications ACCESSWIRE
Dec-15-20 04:00PM	9 Meters Biopharma, Inc. Announces Closing of Offering of Common Stock ACCESSWIRE
Dec-11-20 08:30AM	9 Meters Biopharma, Inc. Prices Public Offering of Common Stock ACCESSWIRE -11.75%
Dec-09-20 07:30AM	9 Meters Biopharma, Inc. Receives Orphan Drug Designation for NM-003, a Proprietary Long-Acting GLP-2, for Prevention of Acute Graft Versus Host Disease (aGvHD) ACCESSWIRE
Dec-07-20 07:30AM	9 Meters Biopharma, Inc. Announces Positive Topline Data for NM-002, a Proprietary Long-Acting GLP-1, in Phase 1b/2a Trial for Short Bowel Syndrome ACCESSWIRE -9.70%
Dec-02-20 11:01AM	Is 9 Meters Biopharma (NMTR) A Good Stock To Buy Now? Insider Monkey
Nov-16-20 07:30AM	9 Meters Biopharma Announces Positive Preclinical Data for NM-102, a Gut Microbiome Modulator in an Immune Checkpoint Inhibitor Failure Model ACCESSWIRE +7.50%
01:51AM	What Type Of Shareholders Own The Most Number of 9 Meters Biopharma, Inc. (NASDAQ:NMTR) Shares? Simply Wall St.
Nov-09-20 07:30AM	9 Meters Biopharma, Inc. Provides Business Update and Announces Third Quarter 2020 Results ACCESSWIRE
Nov-02-20 08:00AM	9 Meters Biopharma, Inc. to Participate in the Following November Virtual Investor Conferences ACCESSWIRE
Sep-08-20 08:30AM	9 Meters Biopharma, Inc. to Participate in September Investor Conferences ACCESSWIRE
Aug-31-20 08:30AM	9 Meters Biopharma, Inc. Announces Formation of Scientific Advisory Board ACCESSWIRE +7.73%
Aug-13-20 04:30PM	9 Meters Biopharma, Inc. Highlighted at Upcoming Truist Securities' Catalyst Conference Call Series: "Prepping Ahead of Data" ACCESSWIRE
Aug-12-20 04:30PM	9 Meters Biopharma, Inc. Provides Business Update and Announces Second Quarter 2020 Results ACCESSWIRE
Aug-04-20 09:30AM	9 Meters Biopharma, Inc. to Participate in August Investor Conferences ACCESSWIRE
Jul-28-20 07:30AM	9 Meters Biopharma, Inc. Announces Issuance of Patent for Use of Larazotide in Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) ACCESSWIRE
Jul-21-20 07:45AM	9 Meters Biopharma, Inc. Doses the First Patients in Phase 1b/2a Clinical Trial in Short Bowel Syndrome ACCESSWIRE +5.38%
Jul-13-20 10:26AM	SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating 9 Meters Biopharma, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire -8.48%
Jul-06-20 04:15PM	9 Meters Biopharma, Inc. Appoints Michael T. Constantino to Board of Directors ACCESSWIRE
Jul-02-20 07:30AM	9 Meters Biopharma, Inc. to Participate in BMO Capital Markets' "Hidden Gems in Healthcare Conference Call Series" ACCESSWIRE -11.37%
Jun-29-20 07:30AM	9 Meters Biopharma, Inc. Amends Definition of Primary Endpoint for Phase 3 Trial in Celiac Disease After Consultation with FDA ACCESSWIRE
Jun-24-20 04:05PM	9 Meters Biopharma, Inc. Initiates Phase 1b/2a Clinical Trial in Short Bowel Syndrome ACCESSWIRE
May-11-20 07:00AM	9 Meters Biopharma, Inc Receives Thorough QT Study Waiver by FDA for Larazotide Being Studied for Celiac Disease ACCESSWIRE +15.00%
May-07-20 07:00AM	9 Meters Biopharma, Inc Announces the Closing of Naia Rare Diseases Acquisition ACCESSWIRE +17.78%
May-05-20 06:30AM	9 Meters Biopharma Hosting Research and Development Day ACCESSWIRE
May-04-20 05:30PM	9 Meters Biopharma, Inc Announces the Closing of $22.5 Million Private Placement Funding ACCESSWIRE -10.71%

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is based in Raleigh, North Carolina.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Temperato John	Chief Executive Officer	May 18	Buy	0.45	50,000	22,285	1,302,522	May 19 04:09 PM
Sirgo Mark A	Director	May 18	Buy	0.47	106,383	50,000	1,385,428	May 19 04:01 PM
Temperato John	Chief Executive Officer	Mar 03	Buy	0.56	100,000	55,590	1,252,522	Mar 04 08:00 AM
Sirgo Mark A	Director	Mar 03	Buy	0.58	86,450	50,002	1,279,045	Mar 07 08:01 AM
Sirgo Mark A	Director	Dec 02	Buy	0.89	50,000	44,500	1,242,595	Dec 03 07:34 AM
Temperato John	Chief Executive Officer	Nov 18	Buy	1.05	50,000	52,500	1,152,522	Nov 19 07:31 AM
Sirgo Mark A	Director	Nov 18	Buy	1.06	20,000	21,200	1,192,595	Nov 22 07:30 AM
Sitar Edward J	Chief Financial Officer	Sep 14	Buy	1.22	15,000	18,300	194,338	Sep 15 08:12 AM
Sirgo Mark A	Director	Sep 07	Buy	1.36	73,529	99,999	1,172,595	Sep 08 08:15 AM
Constantino Michael T.	Director	Aug 24	Buy	1.14	18,000	20,520	52,108	Aug 26 08:18 AM
Sirgo Mark A	Director	Aug 20	Buy	1.10	25,000	27,500	1,099,066	Aug 23 08:15 AM
Temperato John	Chief Executive Officer	Aug 18	Buy	1.05	25,000	26,250	1,102,522	Aug 19 08:16 AM
OrbiMed Israel GP Ltd.	10% Owner	Jun 25	Sale	1.21	15,989,876	19,347,750	8,565,974	Jun 25 07:08 PM
OrbiMed Israel GP Ltd.	10% Owner	Jun 24	Sale	1.38	319,255	440,572	24,555,850	Jun 25 07:08 PM
OrbiMed Israel GP Ltd.	10% Owner	Jun 23	Sale	1.36	841,650	1,144,644	24,875,105	Jun 25 07:08 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience